Visible Lesion Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Visible Lesion. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Visible Lesion receives a directional strategic score of 60/100, combining unmet need (76/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (83/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

A localized pathological or traumatic structural change, damage, deformity, or discontinuity of tissue, organ, or body part.

The reproducible entity is Patsnap disease ID 36609fa8bece4207b887d409854a3271. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Epidemiological Features and Spatial-Temporal Clustering of Visceral Leishmaniasis — China, 2011–2022 Epidemiological Features and Spatial-Temporal Clustering ofVisceral Leishmaniasis — China, 2011–2022

Visceral leishmaniasis (VL) is the second deadliest parasitic disease globally, caused by Leishmania spp. and transmitted through the bite of female sandflies (1). The World Health Organization (WHO) classifies VL as a neglected tropical disease and prioritizes its elimination in the Roadmap for the Prevention and Control of Neglected Tropical Diseases 2021–2030 (2). China reports three VL types: anthroponotic visceral leishmaniasis (AVL), mountain-type zoonotic visceral leishmaniasis (MT-ZVL), and desert-type zoonotic visceral leishmaniasis (DT-ZVL), each exhibiting distinct epidemiological characteristics (3). Once hyperendemic across 16 provincial-level administrative divisions (PLADs) north of the Yangtze River in the 1950s, VL was largely eliminated in most endemic areas of China by the 1980s, with few cases reported in Xinjiang, Gansu, Sichuan, Shaanxi, and Shanxi PLADs (3). However, recent environmental changes have led to a resurgence in VL incidence. Understanding the epidemiological features and spatial-temporal clustering of this disease is crucial. This study analyzed VL case data from the National Notifiable Disease Reporting System (NNDRS) between 2011 and 2022. Joinpoint regression and spatial-temporal clustering analysis identified epidemiological features and VL hotspots. Findings indicate a large-scale MT-ZVL resurgence and new incidence hotspots within the Loess Plateau and its extensions. These findings underscore the need for proactive measures, particularly addressing the disease burden in children. This study provides policymakers with valuable insigh

Review the epidemiology source

Epidemiology evidence 2: Epidemiological Characteristics of Visceral Leishmaniasis — Shanxi Province, China, 1950–2019 Epidemiological Characteristics of Visceral Leishmaniasis— Shanxi Province, China, 1950–2019

System, and included detailed information such as age, gender, occupation, date of onset, and address of each case. Demographic data came from the public website of the Chinese Statistics Bureau (https://data.stats. gov.cn/). VL cases reported from 2005 to 2019 were diagnosed using the Criterion of Visceral Leishmaniasis Diagnosis of China (WS 258–2006) and based on clinical manifestations and rk39 test results (1). Early case diagnosis was based on pathogenic examination of bone marrow smears and clinical manifestations. SPSS software (version 22.0, IBM, New York, USA) was used for data processing and analysis. We estimated prevalence trends from 1950 to 2019 and analyzed season, population, and regional distribution data for 2005 to 2019. The data showed that the prevalence of VL in Shanxi Province was very high in the 1950s, but decreased sharply after the 1960s, although there was an outbreak in 1972. From 1974 to 2004, VL was almost nonexistent in Shanxi Province, with only sporadic cases and an annual case count that never exceeded five. Since 2014, reported cases of VL had increased rapidly in Shanxi, with an annual rate of increase of 63.7%. The number of VL cases reported each year had been over 20 in the last three years, and was 47 in 2019 (Figure 1). From 2005 to 2019, 140 VL cases were reported in Shanxi Province; 96 among males and 44 among females for a male∶female ratio of 2.2∶1. The youngest case was a 19-day infant, the oldest was 85 years old, and the median age was 21 years old. There were 58 cases under the age of 3, accounting for 41.4% of reported cas

Review the epidemiology source

Epidemiology evidence 3: Prevalence and incidence of systemic lupus erythematosus in Thailand based on national health data Prevalence and incidence of systemic lupus erythematosus in Thailand based on national health data

Women accounted for 90.9% of prevalent cases (n=50 851), yielding a female-­to-­male ratio of 9.6: 1. The mean (SD) age in 2017 was 40.0 (15.2) years and rose slightly over follow-­up (41.8 years in 2020). Regionally, the northeast contributed the largest share of patients (35.6 %), whereas the highest crude rate occurred in the south (178.5/100 000). Total person-­time at risk during 2018–2020 was 196.4 million person-­years. Prevalence On 1 July 2017, the point prevalence was 85.8/100 000 (95 % CI 85.1 to 86.5). The period prevalence for 2017– 2020 was 84.5/100 000 (95 % CI 83.9 to 85.1) (table 2). Incidence From 2018 to 2020, there were 15 403, 16 243 and 15 925 new diagnoses annually (table 1), corresponding to annual incidence rates of 23.6, 24.8 and 24.3 per 100 000 person-­years, respectively. The cumulative incidence over the 3-­year period was 72.7/100 000 (95 % CI 72.0 to 73.4) (table 3), based on 196.4 million person-­years at risk. Geographical distribution The northeast contributed the largest share of cases (35.6 %), whereas the highest crude rate occurred in the south (178.5/100 000), and consistently the highest annual incidence (60.0 (2018), 53.9 (2019) and 57.3 (2020) per 100 000 person-­years). Cluster maps show provincial concentrations in Khon Kaen (Northeast), Surat Thani (South) and Phrae (North) (figure 1). DISCUSSION We estimated national SLE rates using Ministry of Public Health data. Point prevalence on 1 July 2017 was 85.8/100 000; period prevalence 2017–2020 was 84.5/100 000. The cumulative incidence 2018–2020 reached 72.7/100 000, with annual r

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Visible Lesion, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Visible Lesion thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: PTH1R

G protein-coupled receptor for parathyroid hormone (PTH) and for parathyroid hormone-related peptide (PTHLH) (PubMed:10913300, PubMed:18375760, PubMed:19674967, PubMed:27160269, PubMed:30975883, PubMed:35932760, PubMed:8397094). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of downstream effectors, such as adenylate cyclase (cAMP) (PubMed:30975883, PubMed:35932760). PTH1R is coupled to G(s) G alpha proteins and mediates activation of adenylate cyclase activity (PubMed:20172855, PubMed:30975883, PubMed:35932760). PTHLH dissociates from PTH1R more rapidly than PTH; as consequence, the cAMP response induced by PTHLH decays faster than the response induced by PTH (PubMed:35932760).

The mechanism anchor is PTH1R. It is a pathway hypothesis, not a claim that every Visible Lesion patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 2070 registered studies. Recent sampled records include:

• JPRN-jRCT2032260420 — Prospective, Multicenter, Single-Arm, Pre-Market Study of the Shockwave Intravascular Lithotripsy (IVL) System with the investigational SWM-007 Catheter; 募集中; Not Applicable; sponsor Shockwave Medical, Inc.; enrollment 45.
• ChiCTR2600130486 — Construction of a high-risk population identification and early screening pathway for pancreatic lesions based on the PANCREAS scale; Not yet recruiting; Early Phase 1; sponsor Peking Union Medical College Hospital, Beijing Union Medical College Hospital, Chinese Academy of Medical Sciences; enrollment 1600.
• ChiCTR2600130353 — A Multicenter Clinical Study on Interpretable Artificial Intelligence-assisted Diagnosis Using Thyroid Ultrasound Imaging; Not yet recruiting; Not Applicable; sponsor The Second Affiliated Hospital of Xi'an Medical University; enrollment not stated.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

The search returned 1 recent directly matched transaction records:

• Johnson & Johnson acquires Shockwave Medical, Inc. (2024-04-05). Review stage, rights, territory, milestones and disclosed economics before using it as a comparable.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate PTH1R relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Visible Lesion merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if PTH1R modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Visible Lesion is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.